Last reviewed · How we verify
anti-pseudomonal penicillin
Anti-pseudomonal penicillins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing cross-linking of peptidoglycan, with enhanced activity against Pseudomonas aeruginosa compared to standard penicillins.
Anti-pseudomonal penicillins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing cross-linking of peptidoglycan, with enhanced activity against Pseudomonas aeruginosa compared to standard penicillins. Used for Serious infections caused by Pseudomonas aeruginosa and other gram-negative bacteria, Hospital-acquired pneumonia, Febrile neutropenia in immunocompromised patients.
At a glance
| Generic name | anti-pseudomonal penicillin |
|---|---|
| Sponsor | Vanderbilt University Medical Center |
| Drug class | Beta-lactam antibiotic (anti-pseudomonal penicillin) |
| Target | Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
These beta-lactam antibiotics work by disrupting bacterial cell wall integrity through inhibition of peptidoglycan cross-linking. Anti-pseudomonal penicillins (such as piperacillin and ticarcillin) have broader gram-negative coverage and greater activity against Pseudomonas aeruginosa than aminopenicillins, making them suitable for serious infections caused by this opportunistic pathogen. They are often combined with beta-lactamase inhibitors to extend coverage against beta-lactamase-producing organisms.
Approved indications
- Serious infections caused by Pseudomonas aeruginosa and other gram-negative bacteria
- Hospital-acquired pneumonia
- Febrile neutropenia in immunocompromised patients
- Intra-abdominal infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Allergic reactions (including anaphylaxis)
- Clostridium difficile-associated diarrhea
- Phlebitis at injection site
Key clinical trials
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
- Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea (NA)
- Effect of Antibiotic Choice On ReNal Outcomes (ACORN) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-pseudomonal penicillin CI brief — competitive landscape report
- anti-pseudomonal penicillin updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI